<?xml version="1.0" ?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:seo="http://purl.org/seo/elements/1.0/" version="2.0">
	<channel>
		<title>Harm Reduction Therapeutics, Inc. News Releases</title>
		<link>https://feeds.newsfilecorp.com/company/9916</link>
		<description>Latest news from Harm Reduction Therapeutics, Inc., as distributed by TMX Newsfile.</description>
		<language>en</language>
		<copyright>CopyRight (c) 2026, Newsfile Corp. All Rights Reserved.</copyright>
		<managingEditor>office@newsfilecorp.com (Newsfile Corp.)</managingEditor>
		<webMaster>office@newsfilecorp.com (Newsfile Corp.)</webMaster>
		<lastBuildDate>Thu, 12 Mar 2026 07:34:01 -0400</lastBuildDate>
		<image>
			<url>https://www.newsfilecorp.com/images/newswire/customer-logos/9916.jpg</url>
			<title>Harm Reduction Therapeutics, Inc. News Releases</title>
			<link>https://feeds.newsfilecorp.com/company/9916</link>
		</image>
		<atom:link rel="self" type="application/rss+xml" href="https://feeds.newsfilecorp.com/company/9916"/>
		<item xml:lang="en">
			<title>First Shipment of RiVive(TM) Brings Life-saving Over-The-Counter Naloxone Nasal Spray One Step Closer to Those Who Need It Most</title>
			<link>https://www.newsfilecorp.com/release/191119/First-Shipment-of-RiViveTM-Brings-Lifesaving-OverTheCounter-Naloxone-Nasal-Spray-One-Step-Closer-to-Those-Who-Need-It-Most</link>
			<description>RiVive™ is now available - Remedy Alliance has begun distributing RiVive to community harm reduction groups working to save lives that would otherwise be lost to opioid overdoseNonprofit Harm Reduction Therapeutics will begin fulfilling orders for RiVive more broadly in early 2024, making it available across the US for free of charge or at a low breakeven cost Harm Reduction Therapeutics is seeking additional funding partners who can save lives by helping to increase the manufacturing of RiVive,...&lt;img src="https://api.newsfilecorp.com/newsinfo/191119/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Mon, 18 Dec 2023 09:00:00 -0500</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/191119</guid>
		</item>
		<item xml:lang="en">
			<title>FDA Approval of RiVive(TM) Is a Critical Milestone in Making Emergency Treatment of Opioid Overdose More Widely Available</title>
			<link>https://www.newsfilecorp.com/release/175286/FDA-Approval-of-RiViveTM-Is-a-Critical-Milestone-in-Making-Emergency-Treatment-of-Opioid-Overdose-More-Widely-Available</link>
			<description>RiVive™, a naloxone nasal spray that is easy to use, will be available over-the-counter Unlike other opioid overdose products, Harm Reduction Therapeutics will make RiVive™, which can save lives, available for free or at low breakeven costPittsburgh, Pennsylvania--(Newsfile Corp. - July 28, 2023) - Harm Reduction Therapeutics (HRT), Inc., a nonprofit pharmaceutical company, announced today that FDA has approved OTC RiVive™ (naloxone HCl nasal spray 3 mg) for the emergency treatment of opioid...&lt;img src="https://api.newsfilecorp.com/newsinfo/175286/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;</description>
			<pubDate>Fri, 28 Jul 2023 13:45:00 -0400</pubDate>
			<category domain="https://www.newsfilecorp.com/language">en</category>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/175286</guid>
		</item>
	</channel>
</rss>
